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ABSTRACT 
Background: Although airway eosinophilia is seen as a cardinal feature of asthma, data eosinophilia are still 
lacking on the proportion of the asthma group exhibiting raised airway eosinophilia. This study aimed to assess 
the distribution of sputum eosinophil count and its relationship with methacholine bronchial hyperresponsiveness 
in mild to moderate steroid-naive asthmatic people.  
Methods: Sputum was induced by inhalation of hypertonic saline (NaCl 4.5%) in 118 mild to moderate steroid-
naive asthmatic people consecutively recruited from our outpatient clinic, and in 44 healthy people. The asthma 
group was selected on the basis of an forced expiratory volume in 1 s (FEV1) of > 70% predicted, and a 
provocative methacholine concentration causing a fall of 20% in FEV1 (PC20 methacholine; PC20M) ≤ 16 mg/ml. 
Results: In the asthma group, the median (range) of the percentage and the absolute values of sputum 
eosinophils were 4.8% (0-75) and 38 103/g (0-14 191), respectively, vs 0% (0-2.3) (P < 0.001) and 0 103/g (0-53) 
(P < 0.001) in healthy participants. Based on the 95% percentile for normal values calculated from our healthy 
group, 69% of the asthma group had significantly raised sputum eosinophil count (that is > 2%). In the asthma 
group, multiple regression analysis followed by a stepwise procedure revealed that sputum eosinophil count was 
significantly and inversely associated with PC20M accounting for 16% of its total variance (P < 0.001) while 
neutrophil counts positively related to PC20M accounting for 4% of total variance (P < 0.05). By contrast, no 
significant relationship was found between either eosinophil or neutrophil counts and the slope of forced vital 
capacity (FVC) vs FEV1 from the methacholine challenge. 
Conclusions: We conclude that two-thirds of people in the mild to moderate asthma group had increased sputum 
eosinophilia, which plays a limited role in determining the degree of methacholine airway hyperresponsiveness. 
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Asthma is associated with a peculiar type of airway inflammation featuring Th2 cytokine overexpression and 
eosinophilic infiltration (1, 2). Some bronchoscopic studies have indicated that the extent of airway eosinophilic 
inflammation is proportional to the disease severity as reflected by the intensity of bronchial 
hyperresponsiveness or baseline impairment of lung calibre (3, 4). However, this issue remains controversial (5, 
6). 
The invasive nature of bronchoscopy has certainly been an impediment to large-scale cross-sectional studies on 
airway inflammation in asthma. It is reasonable to believe that the relatively small group sizes studied by 
bronchoscopy may account for the observed discrepancies. The newly developed noninvasive (7, 8) and 
reproducible (9, 10) technique of induced sputum has resolved this and has prompted studies on bronchial  
inflammation in asthma sufferers, on greater numbers of patients than in the past (11-13). This technique has also 
recently made it possible to determine sputum cell counts in a large and representative group of healthy 
participants (14). 
This study aimed to assess the distribution of airway sputum eosinophil count in a very large group of mild to 
moderate steroid-naive people with asthma, and to analyze the relationship between eosinophil count and 
bronchial hyperresponsiveness to methacholine. Bronchial hyperresponsiveness to methacholine was not only 
assessed by measuring the PC20forced expiratory volume in 1 s (FEV1) but also by calculating the slope of the 
fall in forced vital capacity (FVC) vs FEV1 from the methacholine challenge as a reflect of gas-trapping (15). 
To provide a picture as close as possible to what the clinician may encounter in its daily practice, we conducted a 
prospective study on more than 100 consecutive asthmatic patients seen at our outpatient clinic, who were free of 
treatment with inhaled steroids, with baseline FEV1 > 70% predicted. Cellular composition of sputum in the 
asthma group was compared with that found in 44 healthy participants without any evidence of IgE sensitization. 
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MATERIAL AND METHODS 
Participants 
One hundred and twenty-eight mild to moderate nonsmoking asthmatic patients with FEV1 ≥ 70% predicted 
were consecutively recruited from the outpatient clinic at CHU Liege Sart-Tilman between July 1997 and 
September 1999. Asthma was diagnosed on the basis of clinical history of recurrent episodes of wheeze, 
breathlessness and/or cough associated with the demonstration of bronchial hyperresponsiveness to 
methacholine. Participants were considered to have bronchial hyperresponsiveness if a provocative concentration 
ofmethacholine caused a 20% fall in FEV1 (PC20M) of ≤ 16 mg/ml. 
All participants recruited had a clinical history suggestive of asthma for at least 3 months before sputum 
induction. None used inhaled or oral steroids for at least 6 weeks prior to sputum induction. IgE-mediated 
asthma (16) was defined as a positive skin test (wheal ≥ 3 mm when compared to saline) to at least one of the 
most common aeroallergens from our area (house-dust mites, grass pollen, birch pollen, weed pollen, cat and 
dog dander, and mould mixture). Patients were excluded if symptoms suggestive of upper airway viral infection 
started within 4 weeks of sputum induction. 
A group of 47 healthy nonsmoking participants, recruited through a local advertisement, volunteered as a control 
group. This group was used to define the value of "normal sputum eosinophil count". None had evidence of IgE-
mediated reaction (16) or PC20M ≤ 16 mg/ml. Characteristics of all those who produced adequate sputum 
samples are given in Table 1. 
Each subject gave written informed consent and the protocol was approved by the local ethics committee. 
Methacholine challenge 
Participants underwent a methacholine bronchial challenge according to a slightly modified Cockroft's method. 
Each subject inhaled successively by tidal breathing for 2 min fourfold increasing concentrations of 
methacholine chloride (from 0.06 mg/ml to a maximum of 16 mg/ml). The aerosol was generated by a jet nebu-
liser (Micro Mist; Hudson RCI, Temecula, CA, USA) as previously described (17). 
A multifunctional electronic pocket spirometer was used to record the flow-volume curve, connected in real-time 
to a computer (Spirobank, MIR, Rome, Italy). Sixty seconds after each inhalation the participants made a deep 
inspiration to reach total lung capacity, and then immediately gave a forced maximal expiration without breath 
holding. This manoeuvre was repeated three times and the expiratory flow curve with the best FEV1 value was 
selected by the software programme (WINSPIRO, MIR, Italy). Any forced expiration lasting less than 2 s was 
rejected. 
 
Table 1. Subject characteristics 
 Healthy subjects (n = 44) Asthmatics (n= 118) 
Age (years) 32 ±9 35 ± 13 
Sex (male/female) 21/23 53/65 
Skin prick positive 0 93 
Height (cm) 172 ± 13 170 ± 11 
FEV1 (I) 3.92 ± 0.88 3.31 ± 0.80 
FEV1 (%) 104 ± 16 95 ± 12 
FVC (I) 4.45 ± 1.02 3.95 ± 0.98 
FVC (%) 98 ± 14 97 ± 12 
FEV1/FVC* 88 ± 10 81 ± 8 
PC20M (mg/ml) > 16 1.10 (0.03-16) 
Slope FVC vs FEV1 ND 0.85 ± 0.22 
Results are expressed as means ± SD except PC20M which is expressed as geometric mean (range). * Only in 86 patients. ND, not done. 
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The provocative concentration of methacholine causing a 20% fall in FEV1 from baseline (PC20M) was 
calculated by linear interpolation from the dose-response curve. After the provocative test each subject inhaled 
400 µg salbutamol given by metered dose inhaler with a spacer (Volumatic, Glaxo SmithKline, Uxbridge, UK) 
and the sputum induction was performed 30 min later. 
Sputum induction 
Induction was performed using hypertonic saline (NaCl 4.5%) aerosolized by ultrasonic nebulizer (Devilbiss, 
PA, USA) with an output set at 1.5 ml/min for three periods of 5 min (or four periods if no sample was produced 
after 15 min). After each inhalation, the participants rinsed their mouths with tap-water and dried them with 
tissue paper to minimize contamination with saliva. Then they coughed up sputum in a plastic container placed 
at 4°C until processing. For safety reasons, peak expiratory flow rate was monitored after each 5 min inhalation 
period and the challenge was continued if it was > 250 l/min. 
Sputum processing 
Entire sputum was transferred into 50 ml polypropylene tubes (Becton Dickinson, Abingdon, UK), homogenized 
with an equal weight of dithiothreitol [DTT] (Calbiochem, La Jolla, CA, USA) 0.01 M and processed as 
previously described (18). Total cell count and squamous cell count were made using a hemocytometer.  
Samples were acceptable if the squamous cell count was <80% (10). The success rate of the sputum induction, as 
defined by the collection of a sample with a squamous cell count of <80%, reached 94% in healthy participants 
(44 out of 47) and 92% in the asthma group (118 out of 128) (Table 1). The differential cell count was performed 
on cytospins stained with Diff-Quick (Dade, Marburg, Germany) after counting 400 cells. 
Statistical analysis 
Sputum cell counts were presented as mean ± SD and median (range). Comparisons of sputum cell counts 
between the asthma group and healthy participants were performed by an unpaired Student's t-test, or by a 
Mann-Whitney test when distribution of the data was not parametric. The Kolomogorov-Smirnoff test was used 
to assessed the normality of the cell count distribution. Normal eosinophil count was determined by calculating 
the 95% percentile from the healthy group. Abnormally raised sputum eosinophil counts were those with values 
above the 95% percentile. Linear regression analysis was performed on the FVCs recorded at each step of the 
methacholine challenge against the corresponding FEV1. The slope of the regression was used as an index of 
gas-trapping. The relationship between methacholine bronchial hyperesponsiveness and the different sputum cell 
counts was assessed by calculating Pearson's correlation coefficient after log transformation of both PC20M and 
absolute cell count values. As several variables were found to be associated with PC20M, a multiple stepwise 
regression analysis was performed. When cell count was 0 it was arbitrarily assigned a 1-value to make log 
transformation possible. P-values < 0.05 were considered as statistically significant. 
RESULTS 
Sputum cell counts 
Total and differential cell counts in healthy participants and the asthma group appear in Table 2. The percentage 
of squamous cells, macrophages, and neutrophils were normally distributed, but this was not the case for the 
percentages of eosinophils, lymphocytes and epithelial cells, nor the total cell counts. The asthma group had 
greater percentages and greater absolute values of sputum eosinophils than healthy participants (P < 0.001 for 
both). There was no difference between the groups with respect to the other cell types, nor with respect to the 
total cell counts. 
Based on the values of sputum eosinophil count in healthy participants, we found that 69% (82/118) of the 
asthma group had significantly raised sputum eosinophil count (> 2% > 95% percentile of control group). The 
distribution of sputum eosinophil count showed that half of the asthma group had less than 4.8% sputum 
eosinophils, whereas those with an eosinophil percentage greater than 20% only represented 17% (21 out of 118) 
of the group (Fig. 1). 
Relationship between sputum cell count and methacholine bronchial responsiveness 
After simple linear regression PC20FEV1 methacholine was found to be inversely related to sputum eosinophil (P 
< 0.0001; Fig. 2A) and lymphocyte counts (r = - 0.19, P < 0.05). By contrast, the slope FVC/ FEV1 showed no 
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relation to sputum counts of eosinophils or other cells (P > 0.05; Fig. 2B). 
The relationship between sputum cell counts, baseline airway calibre, and PC20FEV1 methacholine was further 
assessed by multiple regression analysis. PC20M was significantly influenced by sputum cell counts and baseline 
airway calibre with a global variance R reaching 29% (P < 0.001) (Table 3). The three variables significantly 
contributing to the global variance after the stepwise procedure were the eosinophil count, the neutrophil count 
and the FEV1 % predicted, accounting for up to 16% (P < 0.001), 4% (P < 0.05) and 4% (P < 0.05) of the total 
variance, respectively. However, eosinophil count was inversely related to PC20M, but the latter (PC20M) 
positively related to both neutrophil count and FEV1. 
 
Table 2. Sputum cell composition in healthy participants and mild to moderate the asthma group 
Healthy subjects Asthmatics  
 
Mean (± SD) Median (range) Mean (± SD) Median (range) 
Squamous % 13 (9.1) 13.5 (0-33) 15.8 (10.2) 14 (0-61) 
Total nonsquamous 106/g 1.09 (0.9) 0.80 (0.17-4.42) 2.10 (4.97) 0.73 (0.16-37.8) 
Macrophages % 52.6 (17.4) 55 (9-85) 45.6 (21.2) 46.6 (0-87.8) 
 103/g 527 (68) 382 (27-2238) 690 (1147) 325 (0-7914) 
Lymphocytes % 1.3 (1.4) 1 (0-5.2) 1.2 (1.4) 0.8 (0-7.4) 
 103/g 15 (25) 7 (0-150) 22 (37) 10 (0-217) 
Neutrophils % 31.8 (22.8) 26.3 (0.8-87) 29.9 (23.5) 23.8 (0-86.4) 
 103/g 415 (587) 202 (1-2890) 811 (259) 179 (0-20 390) 
Eosinophils % 0.3 (0.6) 0 (0-2.3) 10.9 (13.6) 4.8 (0-75) 
 103/g 5(11) 0 (0-53) 361 (1515) 38 (0-14 191) 
Epithelial cells % 13 (11.5) 10 (0-55.2) 11 (10.4) 9 (0-64.5) 
 103/g 115 (120) 68 (0-440) 185 (512) 59 (0-4909) 
 
Figure 1. Distribution of sputum eosinophil count expressed as a percentage of total cells in patients (n = 118) 
in the mild to moderate steroid-naive asthma group. 
 
DISCUSSION 
Our study describes the distribution of sputum eosinophil counts and its relationship to methacholine bronchial 
responsiveness in a large population of mild to moderate steroid-naive asthma patients, consecutively recruited 
from our outpatient clinic. When compared to healthy nonatopic participants, 69% of the asthma group had 
abnormally raised sputum eosinophilia; this was significantly associated with the severity of methacholine 
bronchial hyperresponsiveness assessed by the PC20FEV1. 
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Figure 2. Relationship between the sputum eosinophil count and PC20 FEV1 methacholine (n = 118) (upper 
panel) and the slope FVC/FEV1 (n = 86) (lower panel). 
 
Although there is general endorsement of the statement that asthma is an eosinophilic bronchitis, no data are yet 
published about the proportion of asthma patients with abnormally high airway eosinophilia. To our knowledge, 
this study is the first to look prospectively at the distribution of sputum eosinophil counts in a large population of 
mild to moderate steroid-naive people with asthma, to establish the proportion of who have significantly raised 
eosinophil counts. This obviously requires definition of normal values, so it is essential to assess airway 
inflammation in a sufficiently large group of healthy participants. 
The normal sputum eosinophil values found in our healthy participants are very close to those recently reported 
by Belda et al. (14) in a group of more than 100 participants. There was a wide range of sputum eosinophil 
counts among the patients, but most had a percentage of sputum eosinophils significantly greater than the 95% 
percentile of a population of nonatopic healthy participants (> 2%), and approximately one-fifth displayed a 
sputum eosinophil count exceeding 20%. However, it is worth noting that approximately half of the asthma 
group had sputum eosinophil counts less than 5%. This may be important for screening for clinical studies that 
assess antiinflammatory drugs in asthma, in patients selected on the basis of sputum eosinophilia (19). 
One interesting observation of this study is that about one-third of the steroid-naive asthma group are non-
eosinophilic—which stems the fact that symptoms of asthma associated with methacholine bronchial 
hyperresponsiveness do not necessarily translate to increased sputum eosinophilia. Recent data have suggested 
that the efficacy of inhaled corticosteroids in attenuating methacholine bronchial hyperresponsiveness and 
symptom scores in asthma depends on a increased numbers of eosinophils in the airway before starting the 
treatment (20). Thus, those with noneosinophilic asthma certainly deserve further attention, in terms of their 
response to drugs such as theophylline, cromoglycate, or leukotriene receptor antagonists that are used as 
controller medications. 
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Table 3. Multiple regression analysis of the relationship between methacholine bronchial responsiveness and 
sputum cytology and baseline lung calibre in the asthma group 
PC20 methacholine  
 Global variance R² Partial regression coefficient β (SE) P value 
 0.29  0.0006 
Macrophages  0.08 (0.14) 0.58 
Lymphocytes  - 0.10 (0.08) 0.23 
Neutrophils  0.28 (0.10) 0.006 
Eosinophils  - 0.20 (0.06) 0.001 
Epithelial cells  - 0.03 (0.09) 0.71 
FEV1  0.02 (0.008) 0.007 
PC20M is the dependent variable. Cell absolute counts and FEV1 % predicted are the independent variables. SE, standard error. 
 
The extent of sputum eosinophilia in the steroid-free asthma patients appears to contribute weakly but 
significantly to the severity of methacholine bronchial hyperresponsiveness. In a model including sputum cell 
count and baseline FEV1 as independent variables and PC20FEV1 as the dependent variable, stepwise multiple 
regression analysis showed that sputum eosinophils accounted for 16% of the variation in PC20M. Although 
weak, the contribution of eosinophils to methacholine bronchial hyperresponsiveness should not be neglected 
because it might underlie the fast and limited change in PC20M that follows treatment with inhaled steroids (20). 
The weak relationship between sputum eosinophil count and PC20M clearly points to the fact that severe 
bronchial hyperresponsiveness may be seen without prominent eosinophilia and that, conversely, bronchial 
hyperresponsiveness sometimes remains mild despite massive infiltration of the airway with eosinophils. This is 
in keeping with previous studies that show high sputum eosinophil counts in chronic cough without asthma (21), 
in rhinitis (22), or in inflammatory bowel disease (23). However, it is possible that the relationship between 
sputum eosinophilia and bronchial hyperresponsiveness may have been stronger if bronchial responsiveness was 
assessed with indirect, potentially more clinically relevant bronchocon-strictors such as adenosine (24,25) or 
bradykinin (26) instead of methacholine. 
Surprisingly, neutrophils contributed to PC20M in an opposite manner to eosinophils, i.e. more neutrophils in the 
airway mean a higher PC20M. This suggests that neutrophils protect against severe bronchial 
hyperresponsiveness in mild to moderate steroid-naive asthma even if the reasons are unclear at present. This 
contrasts with the supposedly active role of the cell in severe asthma, particularly in patients resistant to 
corticosteroids (12, 27). One interpretation is that asthma that remains mild to moderate without inhaled steroid 
therapy has very different cell mechanisms to those of asthma that is moderate to severe with inhaled and/or oral 
steroid therapy. 
Baseline airway calibre is an important determinant of nonspecific bronchial hyperresponsiveness in the general 
population (28). However, this relationship is less clear in asthma where it is common to see patients with 
normal lung function and severe bronchial hyperresponsiveness. The contribution of baseline FEV1 to the PC20M 
in our study is further weakened by the exclusion of those patients with baseline obstruction. Since neither 
airway eosinophilia nor FEV1 substantially contribute to the level of PC20M in mild to moderate asthma, 
biochemical and/or structural changes in airway smooth muscle or bronchial mucosa are likely to be critical in 
regulating the extent of airway instability (29). 
Finally, PC20FEV1 was significantly related to sputum eosinophil count, but this was not the case for the slope 
FVC/FEV1 which appeared to be almost independent of sputum eosinophil count. This slope may reflect a 
propensity to develop excessive peripheral airway obstruction leading to air-trapping, thus it would suggest that 
sputum eosinophil count does not predict the behaviour of the small airway following inhalation of 
methacholine. However, this is not a surprising lack of association. Inflammation may still contribute to small 
airway dysfunction, as sputum samples are mainly from the proximal airway (30), the abnormal behaviour of 
which is more likely to effect FEV1 than FVC. 
We conclude that most mild to moderate steroid-naive asthma patients have a significantly raised sputum 
eosinophilia, which plays a limited role in methacholine bronchial hyperresponsiveness. 
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